4 Top Stocks That Flaunt Solid Earnings Acceleration
- Invest in stocks such as AxoGen (AXGN), Western Digital (WDC), Accolade (ACCD) and Credo Technology (CRDO) for superb earnings acceleration.
- 01/29/2024
|
Wall Street Analysts Predict a 26.85% Upside in Accolade (ACCD): Here's What You Should Know
- The consensus price target hints at a 26.9% upside potential for Accolade (ACCD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 01/19/2024
|
Why Accolade (ACCD) Stock Might be a Great Pick
- Accolade (ACCD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 01/19/2024
|
Accolade: Remain Confident That FY25 Guided Growth Is Achievable
- I continue to recommend a buy rating with a projected 20% growth in FY25. Recent results show that Accolade beat consensus estimates for revenue and EBITDA, and management expects 20% revenue growth and 2-4% EBITDA margins in FY25. Tailwinds for growth include strong demand for navigation solutions, the health plan channel strategy, GLP-1 growth catalyst, and the recovery in demand for expert medical opinion.
- 01/17/2024
|
Accolade To Present at Upcoming Investor Conferences
- SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the following upcoming investor conferences:
- 01/02/2024
|
Is Accolade (ACCD) Stock Outpacing Its Business Services Peers This Year?
- Here is how Accolade (ACCD) and Adecco SA (AHEXY) have performed compared to their sector so far this year.
- 12/05/2023
|
Accolade To Present at Piper Sandler 35th Annual Healthcare Conference
- SEATTLE, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will be presenting at the Piper Sandler 35th Annual Healthcare Conference in New York on Wednesday, November 29, 2023 at 10:00 am ET. A webcast of the company's fireside chat will be available at ir.accolade.com and a replay will be available for 90 days.
- 11/27/2023
|
Accolade To Present at Stephens Annual Investment Conference
- SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will be presenting at the Stephen Annual Investment Conference in Nashville on Wednesday, November 15, 2023 at 11:00am CT. A webcast of the company's fireside chat will be available at ir.accolade.com and a replay will be available for 90 days.
- 11/08/2023
|
Down -31.39% in 4 Weeks, Here's Why Accolade (ACCD) Looks Ripe for a Turnaround
- Accolade (ACCD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 11/02/2023
|
1 Market-Beating Stock to Buy Near Its 52-Week High
- Eli Lilly's obesity diabetes medicine Mounjaro continues to show excellent prospects. It should be the biggest growth driver behind the company's sales in the coming years.
- 10/19/2023
|
Here's Why Accolade (ACCD) is Poised for a Turnaround After Losing -36.43% in 4 Weeks
- Accolade (ACCD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 10/09/2023
|
Why Shares of Accolade Fell This Week
- While Accolade increased revenue year over year, it is still losing money. Several analysts downgraded their price targets for the stock.
- 10/06/2023
|
Accolade, Inc. (ACCD) Q2 2024 Earnings Call Transcript
- Accolade, Inc. (NASDAQ:ACCD ) Q2 2024 Earnings Conference Call October 4, 2023 4:30 PM ET Company Participants Todd Friedman - Senior Vice President, Investor Relations Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Executive Vice President, Care Delivery and Chief Health Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Jessica Tassan - Piper Sandler Jailendra Singh - Truist Securities Jared Haase - William Blair Glen Santangelo - Jefferies Allen Lutz - Bank of America David Larsen - BTIG Stan Berenshteyn - Wells Fargo Robert Simmons - D.A. Davidson Jack Wallace - Guggenheim Partners John Penny - Canaccord Genuity Ryan MacDonald - Needham and Company Operator Good day, and thank you for standing by, and welcome to Accolade Second Quarter 2024 Earnings Results Conference Call.
- 10/04/2023
|
Accolade (ACCD) Reports Q2 Loss, Tops Revenue Estimates
- Accolade (ACCD) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.66 per share a year ago.
- 10/04/2023
|
Accolade: Consider Both Growth And Profitability
- Accolade is in a good position to meet its revenue growth guidance for both the current fiscal year and long term. There is a risk that ACCD's bottom line could fall short of expectations in subsequent quarters, and investors might be concerned about Accolade's path to profitability for the long run. I rate ACCD stock as a Hold, following my evaluation of the company's revenue growth and profitability for the future.
- 10/03/2023
|
Accolade to Announce Fiscal Second Quarter 2024 Financial Results
- SEATTLE, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal second quarter 2024 financial results on Wednesday, October 4, 2023, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.
- 09/20/2023
|
CORRECTING and REPLACING -- Accolade To Present at Upcoming Investor Conferences
- SEATTLE, Sept. 06, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Sept. 5, 2023 by Accolade, Inc. (NASDAQ: ACCD), please note that in the second bullet, the time of the Morgan Stanley presentation should be 1:35 pm ET, not 8:10 am ET as previously stated. The corrected release follows:
- 09/06/2023
|
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
- Cathie Wood bought shares of Palantir, Intellia Therapeutics, and Accolade on Thursday. Palantir was downgraded by a prominent analyst on Thursday, and it recently posted its weakest quarterly revenue growth as a public company.
- 09/01/2023
|
Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again
- Ark Invest has continued to trim its holdings in Nvidia although it's still a large holder. Meanwhile, the investment firm has been increasing its bets in the biotech sector.
- 08/30/2023
|
Accolade: Leveraging Tech To Deliver Accessible Healthcare
- Accolade is experiencing strong demand due to rising healthcare costs and employers seeking ways to reduce expenses. The company's proprietary technology platform and health assistants provide personalized benefits and health support, leading to significant cost savings for customers. Accolade's unique value proposition and robust technology platform position it well for future growth.
- 07/22/2023
|
Accolade: Growth Reacceleration In FY25 Should Drive Valuation Upside
- I maintain a buy rating for ACCD as I expect growth reacceleration in FY25 which will drive valuation upwards. ACCD's management has raised revenue expectations for FY24 and reiterated long-term revenue targets. Potential risks include rising interest rates and the possibility of management missing profit outlook, which could lead to a lower stock price.
- 07/20/2023
|
Accolade: A Rising Personalized AI-Powered Healthcare Platform
- Accolade Inc. NASDAQ: ACCD is an artificial intelligence (AI) powered healthcare platform that provides personalized healthcare guidance for employers and workers. The platform helps people manage their health by finding the right care and providers.
- 07/11/2023
|
Why Accolade Stock Popped by Almost 7% Today
- The specialty healthcare solutions provider unveiled its latest set of quarterly results. These handily beat analyst estimates on both the top and bottom lines.
- 06/30/2023
|
Accolade, Inc. (ACCD) Q1 2024 Earnings Call Transcript
- Accolade, Inc. (NASDAQ:ACCD ) Q1 2024 Earnings Conference Call June 29, 2023 4:30 PM ET Company Participants Todd Friedman - SVP, IR Rajeev Singh - CEO Steve Barnes - CFO Shantanu Nundy - Chief Health Officer Conference Call Participants Ryan Daniels - Blair Craig Hettenbach - Morgan Stanley Jeff Garrow - Stephens, Inc. Jessica Tassan - Piper Sandler Stephanie Davis - SVB Securities Ryan MacDonald - Needham and Company Jonathan Yong - Credit Suisse Jailendra Singh - Truist Securities Sandy Draper - Guggenheim Stan Berenshteyn - Wells Fargo David Larsen - BTIG Robert Simmons - D.A. Davidson Operator Good day, and thank you for standing by, and welcome to Accolade First Quarter '24 Earnings Results Conference Call.
- 06/29/2023
|
Accolade (ACCD) Reports Q1 Loss, Tops Revenue Estimates
- Accolade (ACCD) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.40 per share a year ago.
- 06/29/2023
|
Accolade to Announce Fiscal First Quarter 2024 Financial Results
- SEATTLE, June 13, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal first quarter 2024 financial results on Thursday, June 29, 2023, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.
- 06/13/2023
|
Accolade To Present at Stifel 2023 Cross Sector Insight Conference
- SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will be presenting at the Stifel 2023 Cross Sector Insight Conference in Boston on Tuesday, June 6, 2023 at 11:30 am ET. A webcast of the event will be available at ir.accolade.com and a replay will be available for 90 days.
- 06/01/2023
|
Accolade: FY25 And Long-Term Targets Inspire Confidence
- ACCD has experienced high demand, with revenue increasing by 5.6% in 4Q23 and a 33% increase in ARR bookings. During the analyst day, ACCD upgraded its FY25 margin target and expressed confidence in reaching $500 million in sales.
- 05/27/2023
|
Accolade Inc CFO Stephen Barnes Sells 631 Shares: An Insider Sell Analysis
- On May 23, 2023, Stephen Barnes, the Chief Financial Officer (CFO) of Accolade Inc ( ACCD , Financial), sold 631 shares of the company. This article will provide an overview of Stephen Barnes, Accolade Inc's business, and an analysis of insider buy/sell transactions and their relationship with the stock price.
- 05/25/2023
|
Accolade Inc CEO Rajeev Singh Sells 1,553 Shares: An Insider Sell Analysis
- On May 23, 2023, Rajeev Singh, the CEO of Accolade Inc ( ACCD , Financial), sold 1,553 shares of the company. This article will provide an analysis of this insider sell, the relationship between insider transactions and stock price, and an overview of Accolade Inc and its CEO, Rajeev Singh.
- 05/25/2023
|
Accolade Inc CEO Rajeev Singh Sells 1,456 Shares
- On May 24, 2023, Rajeev Singh, the CEO of Accolade Inc ( ACCD , Financial), sold 1,456 shares of the company's stock. This move comes amidst a year of both buying and selling activity for Singh, who has sold a total of 10,100 shares and purchased 35,000 shares over the past year.
- 05/25/2023
|
Accolade (ACCD) Upgraded to Buy: What Does It Mean for the Stock?
- Accolade (ACCD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 05/24/2023
|
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May - Bio-Rad Laboratories (NYSE:BIO), Accolade (NASDAQ:ACCD)
- The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
- 05/11/2023
|
Accolade, Inc. (ACCD) Q4 2023 Earnings Call Transcript
- Accolade, Inc. (ACCD) Q4 2023 Earnings Call Transcript.
- 04/27/2023
|
Accolade (ACCD) Reports Q4 Loss, Misses Revenue Estimates
- Accolade (ACCD) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.27 per share a year ago.
- 04/27/2023
|
Accolade to Webcast Analyst Day on May 8, 2023
- SEATTLE, April 24, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will host an Analyst Day at the Wynn Las Vegas on May 8, 2023 and will provide a webcast of the event beginning at 1pm PT.
- 04/24/2023
|
Accolade to Announce Fiscal Fourth Quarter 2023 Financial Results
- SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal fourth quarter 2023 financial results on Thursday, April 27, 2023, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.
- 04/11/2023
|
Healthcare company Accolade lays off workers and closes offices
- Seattle and Philadelphia area-based primary healthcare company Accolade is cutting its workforce and closing or reducing some facilities, according to a recent regulatory filing.
- 03/06/2023
|
Why Shares of Accolade Soared This Week
- Strong revenue growth and encouraging guidance pushed the stock up.
- 01/13/2023
|
Accolade, Inc. (ACCD) Q3 2023 Earnings Call Transcript
- Accolade, Inc. (NASDAQ:ACCD ) Q3 2023 Earnings Conference Call January 9, 2023 4:30 PM ET Company Participants Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Chief Medical Officer Todd Friedman - Senior President of Investor Relations Conference Call Participants Michael Cherny - Bank of America Ryan Daniels - William Blair & Company Cindy Motz - Goldman Sachs Craig Hettenbach - Morgan Stanley Glen Santangelo - Jefferies Jonathan Yong - Credit Suisse William Hoover - Canaccord Genuity Jailendra Singh - Truist Ryan MacDonald - Needham Jessica Tassan - Piper Sandler. Stephanie Davis - SVB Securities Stanislav Berenshteyn - Wells Fargo Robert Simmons - D.A.
- 01/09/2023
|
Accolade (ACCD) Reports Q3 Loss, Tops Revenue Estimates
- Accolade (ACCD) delivered earnings and revenue surprises of 8.20% and 4.43%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?
- 01/09/2023
|
Accolade to Announce Fiscal Third Quarter 2023 Financial Results
- SEATTLE, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will release fiscal third quarter 2023 financial results on Monday, January 9, 2023, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.
- 12/20/2022
|
Accolade Inc. (ACCD) Q2 2023 Results - Earnings Call Transcript
- Accolade Inc. (NASDAQ:ACCD ) Q2 2023 Earnings Conference Call October 6, 2022 4:30 PM ET Company Participants Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Chief Medical Officer Todd Friedman - Senior President of Investor Relations Conference Call Participants Michael Cherny - Bank of America Glen Santangelo - Jeffries Jonathan Yong - Credit Suisse Jailendra Singh - Truist Cindy Motz - Goldman Sachs Craig Hettenbach - Morgan Stanley Stephanie Davis - SVB Securities Richard Close - Canaccord Genuity. Stanislav Berenshteyn - Wells Fargo Dev Weerasuriya - Berenberg.
- 10/06/2022
|
Accolade (ACCD) Reports Q2 Loss, Tops Revenue Estimates
- Accolade (ACCD) delivered earnings and revenue surprises of 7.04% and 5.68%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
- 10/06/2022
|
Accolade (ACCD) Expected to Beat Earnings Estimates: Should You Buy?
- Accolade (ACCD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 09/29/2022
|
Here's Why Accolade Shares Are Trading Higher Today
- Needham analyst Ryan MacDonald reiterated a Buy rating on Accolade, Inc (NASDAQ: ACCD) with a price target of $12. Following a problematic 4QF22, he noted that Accolade bounced back nicely in 1QF23 as the company beat management's initial outlook for.
- 07/01/2022
|
Accolade Moves Higher But Growth Is Slowing
- Accolade (NASDAQ: ACCD) is certainly an interesting play on the health care space providing business and employee services geared toward helping clients navigate the cumbersome health benefits arena. The pandemic helped boost the company's business and has on track to continue growing but there is a fly in the ointment.
- 07/01/2022
|
Accolade, Inc. (ACCD) CEO Rajeev Singh on Q1 2023 Results - Earnings Call Transcript
- Accolade, Inc. (NASDAQ:ACCD ) Q1 2023 Earnings Conference Call June 30, 2022 4:30 PM ET Company Representatives Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Chief Medical Officer Todd Friedman - Senior Vice President of Investor Relations Conference Call Participants Ryan Daniels - William Blair Glen Santangelo - Jefferies Richard Close - Canaccord Genuity Michael Cherny - Bank of America. Cindy Motz - Goldman Sachs Jonathan Yong - Credit Suisse Craig Hettenbach - Morgan Stanley Jeff Garro - Piper Sandler David Larsen - BTIG Ryan MacDonald - Needham Stephanie Davis - SVB Securities Stan Berenshteyn - Wells Fargo Dev Weerasuriya - Berenberg Sandy Draper - Guggenheim Operator Good day!
- 06/30/2022
|
Accolade (ACCD) Reports Q1 Loss, Tops Revenue Estimates
- Accolade (ACCD) delivered earnings and revenue surprises of 45.21% and 3.80%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
- 06/30/2022
|
Accolade (ACCD) Stock Jumps 7.2%: Will It Continue to Soar?
- Accolade (ACCD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 06/27/2022
|
Accolade Announces Participation in June Investor Conferences
- SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will participate in the following upcoming investor conferences. A webcast and replay of each event will be available at ir.accolade.com.
- 06/02/2022
|
Accolade Announces Participation in May Investor Conferences
- SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will participate in the following upcoming investor conferences. A webcast and replay of each event will be available at ir.accolade.com.
- 05/09/2022
|
Why Is Accolade (ACCD) Stock Up Today?
- Today, investors in Accolade and ACCD stock have something to cheer, following a rather dismal end to last week. The post Why Is Accolade (ACCD) Stock Up Today?
- 05/02/2022
|
Accolade Stock Rebounds. It's Upgraded on More Balanced Risk-Reward.
- Wells Fargo upgrades Accolade to Equal Weight from Underweight, saying the stock's current price point creates a more balanced risk-and-reward profile.
- 05/02/2022
|
Why Are Accolade Shares Down Over 40% Today
- Accolade Inc (NASDAQ: ACCD) shares plunged almost 50% after disappointing Q4 FY22 earnings and FY23 guidance. Q4 FY22 revenue increased 58% Y/Y to $93.8 million, beating the consensus of $91.57 million.
- 04/29/2022
|
Accolade stock suffers record plunge after earnings miss, loss of largest customer
- Shares of Accolade Inc. lost nearly half their value Friday, after the personalized virtual health care services company reported a wider-than-expected fiscal fourth-quarter loss, and said it would lose its largest customer at the end of the year.
- 04/29/2022
|
Accolade, Inc. (ACCD) CEO Rajeev Singh on Q4 2022 Results - Earnings Call Transcript
- Accolade, Inc. (NASDAQ:ACCD ) Q4 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Todd Friedman - SVP, IR Rajeev Singh - CEO Steve Barnes - CFO Shantanu Nundy - Chief Medical Officer Conference Call Participants Michael Cherny - Bank of America Ryan Daniels - William Blair Jonathan Young - Credit Suisse Glen Santangelo - Jefferies Jeff Garro - Piper Sandler Ricky Goldwasser - Morgan Stanley Cindy Matson - Goldman Sachs Ryan MacDonald - Needham Sandy Draper - Guggenheim Stephanie Davis - SVB Securities Richard Close - Canaccord Genuity Operator Good day, and thank you for standing by. Welcome to the Accolade Fourth Quarter 2022 Earnings Conference Call.
- 04/29/2022
|
Accolade (ACCD) Reports Q4 Loss, Tops Revenue Estimates
- Accolade (ACCD) delivered earnings and revenue surprises of -17.39% and 1.82%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?
- 04/28/2022
|
Accolade to Announce Fiscal Fourth Quarter and Full Year 2022 Financial Results
- SEATTLE, April 14, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, today announced that it will release fiscal fourth quarter and full year 2022 financial results on Thursday, April 28, 2022, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.
- 04/14/2022
|
Accolade to Participate in the 2022 SVB Leerink Global Healthcare Conference
- SEATTLE, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, will participate in the 2022 SVB Leerink Global Healthcare Conference, including a fireside chat presentation on Friday, February 18, 2022 at 2:20 p.m. E.T. A webcast will be available at ir.accolade.com.
- 02/16/2022
|
Accolade Stock (ACCD): Why The Price Surged Today
- The stock price of Accolade Inc (NASDAQ: ACCD) increased by over 20% during intraday trading today. This is why it happened.
- 01/11/2022
|
Accolade Shares Trade Higher After 117% Jump In Q3 Sales
- Accolade Inc (NASDAQ: ACCD) reported Q3 FY22 sales of $83.5 million, up 117% Y/Y, beating the consensus of $75.89 million. The adjusted EBITDA loss widened to $(11.9) million, and the adjusted gross margin improved from 41.8% to 47%.
- 01/11/2022
|
Accolade, Inc.'s (ACCD) CEO Rajeev Singh on Q3 2022 Results - Earnings Call Transcript
- Accolade, Inc.'s (ACCD) CEO Rajeev Singh on Q3 2022 Results - Earnings Call Transcript
- 01/11/2022
|
Accolade (ACCD) Reports Q3 Loss, Tops Revenue Estimates
- Accolade (ACCD) delivered earnings and revenue surprises of 18.75% and 9.85%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?
- 01/10/2022
|
Earnings Preview: Accolade (ACCD) Q3 Earnings Expected to Decline
- Accolade (ACCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/03/2022
|
Accolade Impresses With Revenue Growth But Faces Operating Losses
- Accolade went public in July 2020, raising $220 million in a U.S. IPO. The firm provides a healthcare information platform for enterprises and end users.
- 12/16/2021
|
Accolade to Announce Fiscal Third Quarter 2022 Financial Results
- SEATTLE, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives, today announced that it will release fiscal third quarter 2022 financial results on Monday, January 10, 2022, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.
- 12/16/2021
|
Accolade: I May Add To My Position
- Accolade has seen continued growth this year.
- 10/18/2021
|
Accolade Brings WellRight's Corporate Wellness Programs into its partner ecosystem
- SEATTLE, Oct. 12, 2021 /PRNewswire/ -- Accolade (Nasdaq: ACCD), a healthcare provider serving millions of people and their families, announced today that WellRight, the provider of the nation's most holistic and comprehensive corporate well-being platform, has joined the company's trusted partner ecosystem. Accolade uses a rigorous methodology to select healthcare partners who are change agents in their respective categories and deliver clinically compelling solutions that combine exceptional health outcomes, service, and experience.
- 10/12/2021
|
Accolade, Inc. (ACCD) CEO Rajeev Singh on Q2 2022 Results - Earnings Call Transcript
- Accolade, Inc. (ACCD) CEO Rajeev Singh on Q2 2022 Results - Earnings Call Transcript
- 10/07/2021
|
Accolade (ACCD) Reports Q2 Loss, Tops Revenue Estimates
- Accolade (ACCD) delivered earnings and revenue surprises of 4.44% and 4.04%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock?
- 10/07/2021
|
Accolade Announces Results for Fiscal Second Quarter 2022
- SEATTLE, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal second quarter ended August 31, 2021.
- 10/07/2021
|
Earnings Preview: Accolade (ACCD) Q2 Earnings Expected to Decline
- Accolade (ACCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 09/30/2021
|
Accolade doubles down on personalized mental health services with new offerings
- Health benefits platform company Accolade is expanding its offerings to add two personalized services with an emphasis on mental health, the company announced Tuesday.
- 09/22/2021
|
Accolade introduces new healthcare category: Personalized Healthcare
- SEATTLE, Sept. 21, 2021 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD), the company that provides millions of people and their families with exceptional healthcare, today introduced Personalized Healthcare, a new category that enables a nationally scalable model of value-based care to meet the quadruple aim.
- 09/21/2021
|
Accolade Invites Media, Investors and General Public to Opening of Evolve21
- SEATTLE, Sept. 20, 2021 /PRNewswire/ -- WHAT: Accolade, Inc. (Nasdaq: ACCD) the company that provides millions of people and their families with exceptional healthcare will be making an announcement during the opening keynotes Evolve21, the company's annual customer event being held virtually from September 21-23, 2021.
- 09/20/2021
|
Accolade Stock Inches Higher After Baird Upgrade
- Accolade Inc (NASDAQ:ACCD) is up 0.7% at $45.31 this morning, after Baird upgraded the healthcare technology name to "outperform" from "neutral.
- 09/17/2021
|
Accolade to Participate in Upcoming Investor Conferences
- SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives, will participate in the following upcoming investor conferences:
- 09/07/2021
|
New Strong Sell Stocks for August 17th
- ACCD, CHRS, ELVT, FLGT, and GSHD have been added to the Zacks Rank #5 (Strong Sell) List on August 17, 2021.
- 08/17/2021
|
Accolade to Participate in the 41st Annual Canaccord Genuity Growth Conference
- SEATTLE, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives, will participate in the 41st Annual Canaccord Genuity Growth Conference, including a presentation on Thursday, August 12, 2021 at 11:00 a.m. E.T. An audio webcast and related presentation materials will be available at ir.accolade.com.
- 08/10/2021
|
New Strong Sell Stocks for July 12th
- ACCD, CMTL, HEXO, NTRB, and GP have been added to the Zacks Rank #5 (Strong Sell) List on July 12, 2021
- 07/12/2021
|
Accolade, Inc. (ACCD) CEO Rajeev Singh on Q1 2022 Results - Earnings Call Transcript
- Accolade, Inc. (ACCD) CEO Rajeev Singh on Q1 2022 Results - Earnings Call Transcript
- 07/08/2021
|
Accolade Announces Results for Fiscal First Quarter 2022
- SEATTLE, July 08, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives, today announced financial results for the fiscal first quarter ended May 31, 2021.
- 07/08/2021
|
Will Accolade (ACCD) Report Negative Earnings Next Week? What You Should Know
- Accolade (ACCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/01/2021
|
Accolade Completes Acquisition of PlushCare
- SEATTLE, June 09, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (Nasdaq: ACCD), the company reinventing healthcare by helping people live their healthiest lives, today announced it has completed the acquisition of PlushCare, a leading provider of virtual primary care and mental health treatment. Together with its expert medical opinion capability, Accolade's personalized service will deliver collaborative, comprehensive and holistic care options for the workforces of corporate payers.
- 06/09/2021
|
Booming Telehealth Market Lures More IPOs and M&A Deals
- To make the most of the booming telehealth industry, players are coming up with IPOs and resorting to mergers and acquisitions.
- 06/04/2021
|
Betsy Nabel and Jeff Brodsky join Accolade Board of Directors
- SEATTLE, June 3, 2021 /PRNewswire/ -- Accolade (Nasdaq: ACCD), the company reinventing healthcare, today announced a series of changes to its board of directors that will bolster the board with significant healthcare and human resources expertise. Incoming board member Elizabeth ("Betsy") Nabel, M.D.
- 06/03/2021
|
Accolade to Participate in Upcoming Investor Conferences
- SEATTLE, June 01, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives, will participate in the following upcoming investor conferences:
- 06/01/2021
|
New Strong Sell Stocks for May 17th
- ACCD, CEVA, FCEL, GO, and IIPR have been added to the Zacks Rank #5 (Strong Sell) List on May 17, 2021
- 05/17/2021
|
Accolade to Participate in Upcoming Investor Conferences
- SEATTLE, May 10, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives, will participate in the following upcoming investor conferences:
- 05/10/2021
|
Accolade, Inc. (ACCD) CEO Rajeev Singh on Q4 2021 Results - Earnings Call Transcript
- Accolade, Inc. (ACCD) CEO Rajeev Singh on Q4 2021 Results - Earnings Call Transcript
- 05/08/2021
|
CORRECTION -- Accolade Announces Results for Fiscal Fourth Quarter and Full Year 2021
- SEATTLE, May 05, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Accolade, Inc. (NASDAQ: ACCD) please note that the entire Consolidated Statements of Operations (unaudited) table has been replaced. The corrected release follows:
- 05/05/2021
|
Health benefits platform Accolade to acquire virtual primary care startup PlushCare in $450M deal
- The news: Seattle-based health benefits platform Accolade will pay up to $450 million to acquire PlushCare, a Bay Area-based startup that offers virtual primary care.
- 04/23/2021
|
Accolade to Acquire PlushCare
- SEATTLE, April 23, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (Nasdaq: ACCD), the company reinventing healthcare by helping people live their healthiest lives, today announced it has signed a definitive agreement to acquire PlushCare, a leading provider of virtual primary care and mental health treatment. Together, the two companies intend to provide more seamless consumer access to care for acute, chronic, and preventive health needs with highly rated physicians whether delivered through a virtual setting with PlushCare, or through Accolade's advocacy and navigation solutions that support in-person consultation. The addition of a primary care team will extend Accolade's ability to improve clinical health outcomes for its members and deliver additional cost savings for employers.
- 04/23/2021
|
Accolade: Interesting And Solid Healthcare Play
- Accolade has seen solid growth throughout the second half of 2020, now accompanied by some margin improvements as well.
- 04/06/2021
|
Accolade Announces Pricing of $250 Million Convertible Senior Notes Offering
- SEATTLE, March 25, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (Nasdaq: ACCD) (“Accolade”) announced the pricing of $250 million aggregate principal amount of 0.50% convertible senior notes due 2026 (the “Notes”) in a private placement (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Accolade also granted the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $37.5 million aggregate principal amount of the Notes. The sale of the Notes is expected to close on March 29, 2021, subject to customary closing conditions.
- 03/25/2021
|
Accolade Announces Preliminary Results for Fourth Quarter and Full Year of Fiscal Year 2021
- SEATTLE, March 23, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (Nasdaq: ACCD) today provided preliminary unaudited financial results for the fiscal fourth quarter and year ended February 28, 2021 (fiscal year 2021). Based on current information, the company expects to report revenue for the fiscal 2021 fourth quarter in the range of $56.9 million to $57.9 million and revenue for fiscal year 2021 in the range of approximately $168.0 million to $169.0 million. The company expects to report net loss for the fiscal 2021 fourth quarter in the range of $(7.1) million to $(5.6) million and net loss for fiscal year 2021 in the range of $(53.0) million to $(51.5) million. Adjusted EBITDA is expected to be in the range of $0.6 million to $2.1 million for the fiscal 2021 fourth quarter and in the range of $(29.0) million to $(27.5) million for fiscal year 2021.
- 03/23/2021
|
Accolade Announces Private Offering of $250 Million Convertible Notes
- SEATTLE, March 23, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (Nasdaq: ACCD) (“Accolade”) announced today that it intends to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior notes due 2026 (the “Notes”) in a private placement (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Accolade also intends to grant the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $37.5 million aggregate principal amount of the Notes.
- 03/23/2021
|
Accolade to Participate in Upcoming Investor Conferences
- SEATTLE, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, will participate in the following upcoming investor conferences:
- 02/16/2021
|
Health benefits platform Accolade will pay $460M to acquire telemedicine startup 2nd.MD
- Seattle-based Accolade announced Thursday that it will pay $460 million acquire 2nd.
- 01/14/2021
|
Accolade agrees to buy medical-expert company for $460 million
- Accolade Inc. said late Thursday it has agreed to buy Innovation Specialists LLC, which does business as 2nd.MD, a "leading" expert medical opinion and medical decision support company based in Houston, for $460 million. The deal is expected to close by the end of February, and under the terms of the agreement, Accolade will pay $230 million in cash, $130 million in Accolade stock, and up to $100 million of Accolade stock payable upon certain revenue milestones after the closing.
- 01/14/2021
|
Accolade to Acquire 2nd.MD
- The addition of 2nd.MD's Expert Medical Opinion services to Accolade's portfolio of high-touch, technology-enabled health and benefits solutions expands Accolade's clinical capabilities and creates the market's most comprehensive, integrated healthcare navigation experience.
- 01/14/2021
|
Healthtech firm Accolade is buying telemedicine start-up 2nd.MD for $460 million, sources say
- Just as the digitization of finance has attracted billions in investment and a flurry of M&A, health tech has seen a surge in interest during the pandemic.
- 01/14/2021
|
Accolade Inc.: Bullish Outlook As Its HealthTech Platform Helps Companies Save
- Accolade integrates workplace benefits into one platform and helps organizations save on employee healthcare costs through a virtual concierge service. The company launched its IPO in July of 2020 and is presenting strong growth with a positive operational outlook.
- 01/12/2021
|
Accolade to Participate in 39th Annual J.P. Morgan Healthcare Conference
- SEATTLE, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, will participate in the 39th Annual J.P. Morgan Healthcare Conference, including a presentation on Thursday, January 14, 2021 at 2:50 p.m. E.T. An audio webcast and related presentation materials will be available at ir.accolade.com.
- 01/11/2021
|
Accolade, Inc. (ACCD) CEO Rajeev Singh on Q3 2021 Results - Earnings Call Transcript
- Accolade, Inc. (ACCD) CEO Rajeev Singh on Q3 2021 Results - Earnings Call Transcript
- 01/07/2021
|
Accolade Announces Results for Fiscal Third Quarter 2021
- SEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced financial results for the fiscal third quarter ended November 30, 2020.
- 01/07/2021
|
Accolade to Announce Fiscal Third Quarter 2021 Financial Results
- SEATTLE, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced that it will release fiscal third quarter 2021 financial results on Thursday, January 7, 2021, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.
- 12/23/2020
|
Accolade to Participate in William Blair Healthcare 2021 Focus List Event
- SEATTLE, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, will participate in the William Blair Healthcare 2021 Focus List Event, including a fireside chat presentation by Rajeev Singh, Chief Executive Officer, on Thursday, December 17, 2020. An audio replay will be made available at ir.accolade.com shortly after the event.
- 12/17/2020
|
Accolade to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
- SEATTLE, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, including a fireside chat presentation, on Tuesday, December 1, 2020. An audio replay and related presentation materials will be available at ir.accolade.com.
- 11/20/2020
|
Accolade to Participate in the 29th Annual Credit Suisse Healthcare Conference
- SEATTLE, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, will participate in the virtual 29th Annual Credit Suisse Healthcare Conference, including a fireside chat presentation on Wednesday, November 11, 2020 at 10:15 a.m. E.T. An audio webcast and related presentation materials will be available at ir.accolade.com.
- 10/28/2020
|
Accolade: Still Very Interesting
- Accolade has seen a solid first quarter since it went public. The company is expecting a softer second quarter, yet sees a growth acceleration in the quarters to follow.
- 08/17/2020
|
Accolade, Inc. 2021 Q1 - Results - Earnings Call Presentation
- The following slide deck was published by Accolade, Inc. in conjunction with their 2021 Q1 earnings call..
- 08/14/2020
|
Accolade's (ACCD) CEO Rajeev Singh on Q1 2021 Results - Earnings Call Transcript
- Accolade, Inc. (NASDAQ:ACCD) Q1 2021 Earnings Conference Call August 13, 2020 5:00 PM ET Company Participants Rajeev Singh – Chief Executive Officer Steve Barnes – Chief Financial Officer Conference Call Participants Bob Jones – Goldman Sachs Ricky Goldwasser – Morgan Stanley Michael Cherny – Bank of America Sean Wieland – Piper Sandler Jailendra Singh – Credit Suisse Ryan Daniels – William Blair Matthew Gilmore – Baird Stephanie Davis – SVB Presentation Operator Good afternoon and welcome to the Accolade Fiscal First Quarter 2021 Earnings Call.
- 08/13/2020
|
Accolade Announces Results for Fiscal First Quarter 2021
- * Fiscal first quarter 2021 revenue of $35.9 million, a 25% increase compared to fiscal first quarter 2020 revenue of $28.8 million, driven primarily by strength in new customer adds across segments and offerings * Launched pilot with Defense Health Agency, our first customer in the federal government sector * Provides fiscal second quarter 2021 and full-year fiscal 2021 guidanceSEATTLE, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced financial results for the fiscal first quarter ended May 31, 2020.“Accolade is a mission-driven organization, and in today's environment, our mission is more important than ever. The COVID-19 pandemic has made an already siloed and opaque healthcare system even more complex for people to navigate. During our fiscal first quarter, we delivered positive financial results in a strong demand environment driven in part by that increased complexity,” said Rajeev Singh, Accolade CEO.Mr. Singh continued, “Our commitment to innovating for our customers was demonstrated again via the delivery of a new offering - Accolade COVID Response Care - to help our customers and their employees return to their workplace safely. As we look ahead to the future we see employers increasingly elevating healthcare and benefits and their utilization to a more a strategic buying decision given its role in business continuity.”Financial Highlights for Fiscal First Quarter 2021 ended May 31, 2020 Three months ended May 31, % 2020 2019 change (in millions, except percentages) GAAP Financial Data: Revenue$ 35.9 $ 28.8 25% Net loss$ (14.0) $ (15.9) 12% Non-GAAP Financial Data(1): Adjusted EBITDA$ (9.4) $ (11.7) 19% Adjusted Gross Profit$ 13.8 $ 11.4 21% Adjusted Gross Margin 38.3 % 39.6 % (1) A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."Financial OutlookAccolade provides forward-looking guidance on Revenue and Adjusted EBITDA.For the fiscal second quarter ending August 31, 2020, we expect: * Revenue between $34.5 million and $35.5 million * Adjusted EBITDA, a non-GAAP measure, between $(12.5) million and $(14.5) millionFor the full fiscal year ending February 28, 2021, we expect: * Revenue between $158.0 million and $161.0 million * Adjusted EBITDA, a non-GAAP measure, between $(32.0) million and $(36.0) millionWe have not reconciled guidance for Adjusted EBITDA to net loss, the most directly comparable GAAP measure, and have not provided forward-looking guidance for net loss, because there are items that may impact net loss, including stock-based compensation, that are not within our control or cannot be reasonably predicted.Quarterly Conference Call DetailsThe company will host a conference call today, Thursday, August 13, 2020 at 5:00 p.m. E.T. to discuss its financial results. The call can be accessed by dialing 1-833-519-1281 for U.S. participants, or 1-914-800-3853 for international participants, referencing conference ID 3276322; or via a live audio webcast that will be available online at http://ir.accolade.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.Forward-Looking StatementsThis release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and our financial outlook. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market or industry conditions, regulatory environment and receptivity to our technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key customers or partners; (v) the impact of COVID-19 on our business and results of operation; and (vi) changes to our abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to our prospectus filed with the SEC on July 1, 2020 and the Quarterly Report on Form 10-Q for the fiscal quarter ended May 31, 2020 expected to be filed with the SEC on or about August 13, 2020. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.About Accolade, Inc.Accolade provides personalized health and benefits solutions designed to empower every person to live their healthiest life. Using a blend of cloud-based technologies, specialized support from Accolade Health Assistants® and Clinicians, and integrated data and programs across mobile, online and phone, Accolade navigates people through the healthcare system with trust, empathy and ease. Employers offer Accolade to employees and their families as the single place to turn for all health, healthcare, and benefits questions or concerns, increasing their engagement in benefits and connecting them to high-quality providers and care. By empowering members to make better decisions about their health, Accolade can support members in lowering the cost and complexity of healthcare while achieving consumer satisfaction ratings over 90 percent and an NPS of 60.Investor Contact:Asher Dewhurst, Investor Relations, 443-213-0500, Accolade@westwicke.com; Media Contact:Megan Torres, Public Relations, 206-679-9630, Megan.Torres@accolade.com Financial TablesAccolade, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (unaudited) (In thousands, except share and per share data) May 31, February 29, Assets2020 2020 Current assets: Cash and cash equivalents$ 77,682 $ 33,155 Accounts receivable 2,971 294 Unbilled revenue 234 895 Current portion of deferred contract acquisition costs 1,395 1,368 Current portion of deferred financing fees 279 279 Prepaid and other current assets 14,193 12,944 Total current assets 96,754 48,935 Property and equipment, net 12,598 13,625 Goodwill 4,013 4,013 Acquired technology, net 1,692 2,054 Deferred contract acquisition costs 4,103 3,876 Other assets 1,322 745 Total assets$ 120,482 $ 73,248 Liabilities, convertible preferred stock and stockholders’ deficit Current liabilities: Accounts payable$ 4,940 $ 5,273 Accrued expenses 4,375 6,580 Accrued compensation 26,627 23,838 Deferred rent and other current liabilities 729 674 Due to customers 4,278 4,674 Current portion of deferred revenue 34,444 28,919 Total current liabilities 75,393 69,958 Loans payable, net of unamortized issuance costs 72,524 21,144 Deferred rent and other noncurrent liabilities 5,614 5,523 Deferred revenue 426 396 Total liabilities 153,957 97,021 Convertible preferred stock : Preferred stock; 19,513,996 shares authorized; 19,513,939 issued and outstanding at May 31, 2020 and February 29, 2020, respectively (liquidation value of $239,244 at May 31, 2020) 233,022 233,022 Stockholders’ deficit Common stock par value $0.0001; 65,000,000 shares authorized; 6,381,257 and 6,033,450 shares issued and outstanding at May 31, 2020 and February 29, 2020, respectively 2 2 Additional paid-in capital 68,329 64,071 Accumulated deficit (334,828) (320,868) Total stockholders’ deficit (266,497) (256,795) Total liabilities, convertible preferred stock and stockholders’ deficit$ 120,482 $ 73,248 Accolade, Inc. and Subsidiaries Condensed Consolidated Statements of Operation (unaudited) (In thousands, except share and per share data) Three months ended May 31, 2020 2019 Revenue$ 35,894 $ 28,763 Cost of revenue, excluding depreciation and amortization 22,239 17,435 Operating expenses: Product and technology 11,370 11,246 Sales and marketing 7,315 7,662 General and administrative 5,667 5,563 Depreciation and amortization 1,928 2,160 Total operating expenses 26,280 26,631 Loss from operations (12,625) (15,303) Interest expense, net (1,282) (543) Other expense (15) (34) Loss before income taxes (13,922) (15,880) Income tax expense (38) (23) Net loss$ (13,960) $ (15,903) Net loss per share, basic and diluted$ (1.86) $ (3.
- 08/13/2020
|
A Significant Market Shift To Value Stocks Is Bound To Happen
- A major shift into tech/growth stocks occurred due to the COVID-19 pandemic with the Nasdaq being up 18% YTD. I anticipate that this trend will reverse soon.
- 07/27/2020
|
Accolade to Announce Fiscal First Quarter 2021 Financial Results
- SEATTLE, July 27, 2020 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced that it will release fiscal first quarter 2021 financial results on Thursday, August 13, 2020, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. E.T. on the same day. Conference Call DetailsThe conference call can be accessed by dialing 1-833-519-1281 for U.S. participants, or 1-914-800-3853 for international participants, referencing conference ID 3276322; or via a live audio webcast that will be available online at http://ir.accolade.com.A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.About Accolade, Inc.Accolade provides personalized health and benefits solutions designed to empower every person to live their healthiest life. Using a blend of cloud-based technologies, specialized support from Accolade Health Assistants® and Clinicians, and integrated data and programs across mobile, online and phone, Accolade navigates people through the healthcare system with trust, empathy and ease. Employers offer Accolade to employees and their families as the single place to turn for all health, healthcare, and benefits questions or concerns, increasing their engagement in benefits and connecting them to high-quality providers and care. By empowering members to make better decisions about their health, Accolade can support members in lowering the cost and complexity of healthcare while achieving consumer satisfaction ratings over 90 percent and an NPS of 60.Investor Contact:Asher Dewhurst, Investor Relations, 443-213-0500, Accolade@westwicke.comMedia Contact:Megan Torres, Public Relations, 206-679-9630, Megan.Torres@accolade.comSource: Accolade
- 07/27/2020
|
U.S. IPO Week Ahead: Tax Software Leads A Diverse 7-IPO Week
- Seven IPOs and one SPAC plan to raise $2.1 billion in the week ahead, led by tax software provider Vertex.
- 07/25/2020
|
Mednax, Accolade See Activist Actions
- Starboard Value increased its position in pediatric and neonatal health-services firm Mednax. Carrick Management Partners disclosed an initial investment of 3,508,278 shares in Accolade, a newly public workplace health-benefits manager.
- 07/18/2020
|
Accolade Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced the closing of its initial public offering of 11,526,134 shares of its common stock, inclusive of the full exercise by the underwriters of their option to purchase 1,503,408 shares of common stock, at a price to the public of $22.00 per share. The shares are listed for trading on The Nasdaq Global Select Market under the ticker symbol "ACCD".
- 07/07/2020
|
Accolade - Interesting Tech And Healthcare Offering
- Accolade operates at the intersection of tech and healthcare, an interesting environment to operate in. I see the potential for the business as the company has
- 07/05/2020
|
U.S. IPO Weekly Recap: 3 IPOs Close Out The 2Q In Shortened Holiday Week
- Three IPOs raised $2.3 billion this past week, led by Dun & Bradstreet's billion-dollar deal. All three IPOs upsized their deals and priced above the range. Lem
- 07/03/2020
|
Accolade Announces Pricing of Initial Public Offering
- Accolade, Inc. ("Accolade"), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced the pricing of its initial public offering of 10,022,726 shares of its common stock at a price to the public of $22.00 per share. The shares are expected to begin trading on The Nasdaq Global Select Market under the ticker symbol "ACCD" on July 2, 2020, and the offering is expected to close on July 7, 2020, subject to customary closing conditions. In addition, Accolade has granted the underwriters a 30-day option to purchase up to 1,503,408 additional shares of common stock at the initial public offering price less the underwriting discount and commissions.
- 07/02/2020
|
U.S. IPO Week Ahead: Dun & Bradstreet Returns To Public Market In Shortened 4 IPO Week
- Four IPOs are expected to raise $2 billion before the Fourth of July, led by commercial data analytics provider Dun & Bradstreet. Insurtech startup Lemonade pla
- 06/27/2020
|
Stocks To Watch: Fireworks For Nikola, Tesla And Micron
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 06/27/2020
|
IPO Update: Accolade Proposes Terms For U.S. IPO
- Accolade intends to raise $175 million in a U.S. IPO. The firm provides a healthcare management and relationship platform to enterprises. ACCD has grown revenue
- 06/24/2020
|
Accolade Seeks $100 Million In U.S. IPO
- Accolade has filed to raise $100 million in an IPO, although the final figure may differ. The firm has developed an integrated healthcare and wellness platform
- 03/05/2020
|
